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Summary
 
Interleukin (IL)-12 plays a key role not only in protective innate and adaptive T helper cell type 1
(Th1) responses but also in chronic inflammatory diseases. We report here that engagement of
CD47 by either monoclonal antibody, its natural ligand thrombospondin (TSP), or 4N1K (a
peptide of the COOH-terminal domain of TSP selectively binding CD47) inhibits IL-12 release
by monocytes. The suppression occurred after T cell–dependent or –independent stimulation of
monocytes and was selective for IL-12 inasmuch as the production of tumor necrosis factor
(TNF)-
 
a
 
, IL-1, IL-6, and granulocyte/macrophage colony-stimulating factor was not inhibited.
CD47 ligation did not alter transforming growth factor (TGF)-
 
b
 
 and IL-10 production, and the
suppressive effect on IL-12 was not due to autocrine secretion of TGF-
 
b
 
 or IL-10. The IL-12
inhibition was not mediated by Fc
 
g 
 
receptor ligation, did not require extracellular Ca
 
2
 
1
 
 influx,
but was reversed by two phosphoinositide 3-kinase inhibitors (wortmannin and Ly294002).
Thus, engagement of CD47 on monocytes by TSP, which transiently accumulates at the inflam-
matory site, is a novel and unexplored pathway to selectively downregulate IL-12 response. The
pathway may be relevant in limiting the duration and intensity of the inflammatory response,
and in developing novel therapeutic strategies for Th1-mediated diseases.
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I
 
nterleukin (IL)-12 is a potent proinflammatory and im-
munoregulatory cytokine which plays a crucial role in
innate and adaptive immunity (for a review, see reference
1). IL-12 is produced primarily by activated mononuclear
and polynuclear phagocytes, as well as dendritic cells. IL-12
is released during the early stage of infections caused by a
large variety of bacteria, intracellular pathogens, fungi, and
certain viruses. This early production of IL-12 is T cell in-
dependent and results from the direct interaction of patho-
gens or their products with phagocytic cells. IL-12 rapidly
triggers NK cells and T cells to release IFN-
 
g
 
, which in-
creases not only the bactericidal activity of phagocytes but
also their release of proinflammatory cytokines, including
IL-12 itself. In addition to activating the cells of the innate
immune system, IL-12 and IFN-
 
g
 
 direct the differentiation
of antigen-specific naive T cells into Th1 effectors, produc-
ing high levels of IFN-
 
g
 
 and conferring protection against
intracellular pathogens.
The IL-12/IFN-
 
g
 
 proinflammatory loop initiated during
the early stage of infection is generally of short duration
and is probably downregulated by several mechanisms. For
example, the engagement of phagocytic receptors (CR3,
Fc
 
g
 
, and scavenger receptors) on macrophages by opsonized
bacteria was shown to inhibit IL-12 production (2, 3). Sim-
ilarly, CD46 ligation by measle virus suppresses IL-12 release
(4). Another important physiological inhibitor of IL-12/
IFN-
 
g
 
 production is IL-10, which can also be released by
pathogen-stimulated phagocytes, but at a later stage than
IL-12 (1). Other nonselective inhibitors of IL-12 produc-
tion include cytokines like TGF-
 
b
 
, IL-4, and IL-13, as well
as PGE2, glucocorticoids, and cholera toxin (5–7).
IL-12 is also produced after cognate interaction of CD4
 
1
 
T cells with dendritic cells or monocytes (8). This T cell–
dependent pathway of IL-12 production is mediated through
CD40–CD154 (CD40L) interactions and regulates the level
of IFN-
 
g
 
 production in primary and secondary response to
antigens devoid of intrinsic adjuvant activity, including au-
toantigens (1). Recent evidence further suggests a third
mechanism of IL-12 production which may occur at in-
flammatory sites, without infectious agents or TCR-medi-
ated signals (9). It was found that the addition of IL-15 or
IL-2 to cultures of autologous resting T cells and mono-
cytes induces the production of proinflammatory cytokines
including IL-12 and IFN-
 
g
 
.
The extravasation of T lymphocytes and monocytes
from blood vessels to inflammatory lesions requires interac-
tions with the extracellular matrix (ECM), which is com-
posed of various adhesive glycoproteins and glycosamino- 
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glycans (10). Consequently, molecules that mediate the
physical interactions between the immune cells and the ex-
tracellular environment may play a critical role by imposing
a context in which biological and inflammatory processes
take place. For instance, low molecular weight hyaluronan
was shown to induce IL-12 production by binding CD44
on inflamed macrophages (11). Also, the 
 
b
 
1 and 
 
b
 
2 inte-
grin family of adhesive receptors, expressed by PBMCs,
mediates ECM–cell interactions that deliver costimulatory
signals to the incoming cells. Engagement of 
 
b
 
1 integrins
by fibronectin increases adhesion of T lymphocytes to im-
mobilized ligands (12) and promotes TCR signaling.
CD47 antigen, also known as integrin-associated protein
(IAP), is a widely expressed multispan transmembrane protein
which is physically and functionally associated with 
 
a
 
v
 
b
 
3
integrin, the vitronectin (Vn) receptor (13). Indeed, CD47
 
2
 
cell lines expressed 
 
a
 
v
 
b
 
3 but failed to bind Vn-coated beads.
Moreover, CD47-deficient mice rapidly die of 
 
Escherichia
coli
 
 peritonitis, a phenomenon directly associated with a re-
duction in leukocyte activation in response to 
 
b
 
3, but not
 
b
 
2, integrin ligation (14). More recently, CD47 has been
implicated in leukocyte transendothelial migration (15),
whereas its potential role in immune regulation has not yet
been explored. Its newly described natural ligand, thrombo-
spondin (TSP), is transiently expressed at high concentra-
tion in damaged and inflamed tissues (16, 17). TSP is a homo-
trimeric ECM protein mainly produced by platelets; it may
also be synthesized by monocytes and alveolar macrophages.
In addition to CD47, TSP binds heparan sulfate proteogly-
cans, the 
 
a
 
v
 
b
 
3, 
 
a
 
4
 
b
 
1, 
 
a
 
5
 
b
 
1 integrins, and CD36 (16–18).
We here examine the potential role of CD47 and TSP in
the regulation of cytokine synthesis by monocytes. We re-
port that ligation of CD47 antigen, by mAb or TSP, specif-
ically and selectively inhibits IL-12 production by purified
monocytes in response to T cell–dependent or –indepen-
dent stimuli.
 
Materials and Methods
 
Reagents.
 
Recombinant GM-CSF was provided by Dr. D.
Bron (Institut Bordet, Brussels, Belgium). IFN-
 
g
 
 was obtained
from Genzyme. sCD40L trimeric protein was provided by Drs.
C. Maliszewski and R. Armitage (Immunex Corp., Seattle, WA).
 
Staphylococcus aureus
 
 Cowan I strain (SAC) was used at 0.01%
(wt/vol) (Pansorbin; Calbiochem-Behring) and LPS at 10 
 
m
 
g/ml
(Sigma Chemical Co.). Anti-CD47 mAbs B6H12 (mouse IgG1)
and BRIC126 (mouse IgG2b) were purchased from Serotec.
Isotype-matched negative control mAb (mouse IgG1) was pre-
pared in our laboratory. Anti-CD18 mAb (mouse IgG1; Ameri-
can Type Culture Collection) was used at 10 
 
m
 
g/ml. Neutral-
izing anti–IL-10 mAb (clone 19 F1.1; American Type Culture
Collection) and neutralizing anti–TGF-
 
b
 
 (polyclonal chicken Ig)
were used at 10 and 30 
 
m
 
g/ml, respectively. TSP was purchased
from GIBCO BRL, and EDTA and EGTA were from Sigma
Chemical Co. The 4N1K peptide (KRFYVVMWKK) was ob-
tained from Genosys and corresponds to the COOH-terminal
domain of TSP (16); 4NGG (KRFYGGMWKK) was a gift from
W. Frazier (Washington University, St. Louis, MO).
 
Cell Purification and Culture Conditions: Monocytes.
 
PBMCs were
isolated by density gradient centrifugation of heparinized blood
from healthy volunteers (total
 
 n 
 
5 
 
30) using Lymphoprep (Nyco-
med). Enriched monocytes were prepared by cold aggregation as
described (9), followed by one cycle of rosetting with S-(2-amino-
ethyl) isothiouronium bromide (Aldrich)–treated SRBCs to de-
plete residual T and NK cells. Monocyte purity was shown to be
 
.
 
95% by flow cytometry (FACScan™; Becton Dickinson) using
PE-conjugated anti-CD14 mAb (Ancell).
Monocytes were cultured at 10
 
6
 
/ml in 96-well round-bottomed
Falcon plates (Becton Dickinson). Cultures were performed in
quadruplicate in complete serum-free HB101 medium (Irvine
Scientific) containing Ca
 
2
 
1
 
 (600 
 
m
 
M) and Mg
 
2
 
1
 
 (490 
 
m
 
M) and
supplemented with 2 mM glutamine, 1 mM sodium pyruvate,
10 mM Hepes, 100 IU penicillin, and 100 
 
m
 
g/ml streptomycin.
 
Cytokine Measurement.
 
IL-12p70 release was assessed by a two-
site sandwich ELISA using clone 20C2 as the capture mAb and
clone 4D6 as the second mAb as described (9). Both mAbs were
provided by Dr. M. Gately (Hoffmann-LaRoche, Nutley, NJ). The
sensitivity of the assay was 6 pg/ml. TNF-
 
a
 
 was measured using a
sandwich ELISA as described previously (19), and IL-10 was de-
termined by a sandwich solid-phase RIA using anti–IL-10 mAb
(clone 9D7) as the capture mAb and 
 
125
 
I-labeled anti–IL-10
(clone 12G8) as the detecting probe. IL-1
 
b
 
, IL-6, GM-CSF, and
TGF-
 
b
 
 ELISA kits were purchased from R&D Systems. All of
the measurements were performed in duplicate with a coefficient
variation of 
 
,
 
10%.
 
Statistical Analysis.
 
The paired 
 
t
 
 test was used to determine
statistical significance of the data. 
 
*
 
P 
 
, 
 
0.05; 
 
**
 
P 
 
, 
 
0.01; 
 
***
 
P 
 
,
 
0.005.
 
Results
 
CD47 mAb Selectively Suppresses IL-12 Release by Mono-
cytes.
 
We examined the effect of soluble CD47 mAb on
IL-12 release by purified monocytes costimulated by IFN-
 
g
 
and T cell–dependent (sCD40L and GM-CSF) or –indepen-
dent (SAC) signals. As depicted in Fig. 1 A, CD47 mAb
significantly suppressed IL-12 secretion in response to either
stimuli, whereas isotype-matched IgG1 mouse mAb had no
effect. In agreement with Marth and Kelsall (3), anti-CD18
mAb, used as a cell-binding irrelevant mAb, did not sup-
press IL-12 production (data not shown). We noted an in-
hibition of IL-12 release even when monocytes were cul-
tured with SAC alone, indicating that CD47 mAb did not
simply impair the enhancing effect of IFN-
 
g
 
 on IL-12 pro-
duction. Our unpublished observations revealed a similar
suppressive effect by CD47 mAb after LPS and IFN-
 
g
 
 co-
stimulation.
The blockade of IL-12 production in response to SAC
and IFN-
 
g
 
 was rather selective, since the release of other
monocyte products (TNF-
 
a
 
, IL-1, IL-6, and GM-CSF)
remained largely unaffected (Fig. 1 B). Note a threefold in-
crease in IL-6 secretion, which did not reach statistical sig-
nificance. Cell viability, as determined by trypan blue dye
exclusion, was unchanged. Also, the inhibition of IL-12
was probably not mediated via an increase of autocrine
antiinflammatory cytokines (IL-10 and TGF-
 
b
 
), known to
efficiently downregulate bacteria-induced monokine release
(1). As shown in Fig. 1 C, IL-10 and TGF-
 
b
 
 levels remained
unaffected by CD47 mAb treatment. Moreover, neutralizing 
1177
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anti–IL-10 or anti–TGF-
 
b
 
 antibodies added alone or simul-
taneously did not overcome CD47 mAb–mediated inhibi-
tion of IL-12 production by SAC- and IFN-
 
g
 
–stimulated
monocytes (Fig. 1 D, and data not shown).
 
Thrombospondin Inhibits IL-12 Release.
 
We next evaluated
the effect of TSP, the natural ligand of CD47 (16), on
monokine release. As shown in Table I, TSP significantly
reduced IL-12 production by SAC- and IFN-
 
g
 
–stimulated
monocytes, whereas it slightly enhanced TNF-
 
a
 
 release.
Note that monocytes coexpressed two other TSP receptors
(CD36 and 
 
a
 
v
 
b
 
3 [15]). Since the site of interaction be-
tween CD47 and TSP is limited to the cell-binding domain
(CBD) of TSP, we examined the role of a synthetic peptide
(4N1K) encoding this particular domain (16). We found
that 4N1K, but not control mutant peptide 4NNG, dose-
dependently inhibited IL-12 release in response to SAC and
IFN-
 
g 
 
without affecting TNF-
 
a
 
 production (Fig. 2).
 
CD47 Ligation Suppresses IL-12 Release via an Fc and Ca
 
2
 
1
 
–
independent but Phosphoinositide 3-Kinase–dependent Pathway.
 
This specific inhibition of IL-12 release after CD47 en-
gagement was reminiscent of recent studies reporting that
Fc
 
g
 
R cross-linking selectively downregulated IL-12 secre-
tion in monocytes via an increase in extracellular calcium
influx (2). We analyzed whether this mechanism might be
involved in the CD47 mAb–mediated IL-12 suppression.
First, F(ab
 
9
 
)
 
2
 
 fragments of CD47 mAb dose-dependently
inhibited IL-12p70 release, demonstrating that the inhibi-
tory effect was not Fc mediated (Fig. 3 A). Furthermore,
monovalent Fab fragments still suppressed IL-12 secretion
(Fig. 3 B), suggesting that CD47 mAb either prevented
monocyte/monocyte interactions and the delivery of a
positive signal, or directly delivered to the monocytes a
negative signal for IL-12 production. Second, IL-12 down-
regulation was observed in monocyte cultures supplemented
with a fivefold excess of the Ca
 
2
 
1
 
 and Mg
 
2
 
1
 
 chelating
agents EDTA or EGTA, demonstrating that the suppressive
effect was independent of extracellular Ca
 
2
 
1
 
 influx (Fig. 3 B).
Figure 1. CD47 mAb selectively inhibits IL-12 release by purified
monocytes. (A) Monocytes (106/ml) were cultured with SAC (0.01%; n 5 5),
SAC plus IFN-g (500 U/ml; n 5 12), or sCD40L (1 mg/ml) plus GM-CSF
(25 ng/ml) plus IFN-g (500 U/ml; n 5 6) in the absence or presence of
CD47 mAb (IgG1) or isotype-matched control mAb (cont; 10 mg/ml).
IL-12p70 was measured in the culture supernatants after 20 h. (B) Mono-
cytes were stimulated with SAC and IFN-g (n 5 6) in the presence of
CD47 or control mAb. TNF-a, IL-1b, IL-6, and GM-CSF were mea-
sured after 20 h. Data are mean values 6 SEM of n separate experiments
from n different donors. ***P , 0.005; *P , 0.05. (C) Monocytes were
stimulated with SAC and IFN-g in the presence of CD47 or control mAb; IL-10 and TGF-b were measured after 20 h. Data are mean values 6 SEM
from six experiments using six different donors. (D) Monocytes were stimulated with SAC and IFN-g in the presence of CD47 or control mAb; neutral-
izing anti–IL-10 (10 mg/ml), anti–TGF-b (30 mg), or isotype-matched control mAbs were added to the cultures. Data are mean values of duplicate cul-
tures and represent one of three experiments using three different donors.
Table I. TSP Selectively Inhibits IL-12 Production by Monocytes
IL-12 (pg/ml) TNF-a (ng/ml)
Exp.
1
Exp.
2
Exp.
3
Exp.
1
Exp.
2
Exp.
3
SAC 1 IFN-g 168 1,020 2,120 120 64 87
SAC 1 IFN-g 1 TSP 79 746 1,090 147 83 105
Percent inhibition 53 27 49 – – –
Monocytes (106/ml) were cultured for 20 h with SAC (1:10,000) and
IFN-g (500 U/ml) with or without plastic-coated TSP (10 mg/ml).
Culture supernatants were harvested for cytokine determination as de-
scribed. Exp., experiment.1178 CD47 Regulation of IL-12 Production
Moreover, addition of EDTA or EGTA in the absence of
mAb did not result in inhibition of TNF-a or IL-12 release.
Since TSP signaling of focal adhesion in endothelial cells
requires activation of phosphoinositide 3-kinase (PI 3-K
[20]), we explored the involvement of this pathway in
CD47 mAb–mediated suppression of IL-12 release by us-
ing two PI 3-K inhibitors, wortmannin and Ly294002. We
found that both PI 3-K inhibitors restored IL-12 release in
a dose-dependent manner (Fig. 4) with no effect on TNF-a
secretion (data not shown). However, neither protein ki-
nase C (e.g., H7, HA1004) nor protein tyrosine kinase in-
hibitors (e.g., herbimycin) prevented CD47 mAb–mediated
inhibition of IL-12 release (not shown). Taken collectively,
our results suggest that engagement of CD47 on monocytes
by mAb, its natural ligand TSP, and 4N1K peptide specifi-
cally suppressed IL-12 secretion through an Fc and Ca21–
independent but PI 3-K–dependent pathway.
Discussion
The critical role of IL-12–mediated protection against
mycobacterial infection was recently confirmed in IL-12
receptor–deficient patients (21). Nevertheless, uncontrolled
production of IL-12 is pathogenic in some organ-specific
autoimmune diseases (1) and endotoxic shock (22), under-
scoring the requirement of potent negative regulatory feed-
back mechanisms. The present findings demonstrate that en-
gagement of CD47 by its natural ligand, TSP, or by CD47
mAb, represents a novel pathway to selectively downregulate
IL-12 production.
Inhibition of IL-12 release by CD47 ligation occurred in
activated monocytes through a PI 3-K–dependent pathway.
Indeed, two specific inhibitors of PI 3-K (wortmannin and
Ly294002) overcame CD47-mediated IL-12 suppression
with no effect on TNF-a production. Although these data
are not a definite proof of the involvement of PI 3-K, they
are supported by the observations that TSP-mediated func-
tions such as cell spreading or focal adhesion disassembly
required activation of PI 3-K (20). Besides inhibitory cy-
tokines, including IL-4, IL-10, and TGF-b, which suppress
the production of a large number of proinflammatory
products (e.g., TNF-a, IL-1, IL-6, and IL-12) by activated
monocytes, several monocyte surface receptors reportedly
downregulate IL-12 production in a somewhat selective
manner.  Histoplasma capsulatum and measles virus have been
shown to decrease IL-12 release by signaling through CD11b
and CD46, respectively (3, 4). IL-12 downmodulation that
resulted from scavenger receptor and FcgR ligation is due
to extracellular Ca21 influx (2) and increase in IL-10 pro-
duction in the case of FcgRI (23). In the present study, the
CD47 mAb inhibition was Fc and Ca21 independent since
intact, divalent, and monovalent fragments of CD47 mAb
Figure 2. 4N1K selectively suppresses the production of IL-12 by
monocytes. Monocytes (106/ml) were stimulated with SAC and IFN-g in
the presence of various concentrations of 4N1K (peptide of COOH-ter-
minal domain of TSP) or 4NGG (mutant peptide). IL-12p70 and TNF-a
release were measured after 20 h. Data are mean values of duplicate cul-
tures of one representative of three independent experiments using three
different donors.
Figure 3. Suppression of IL-12 production by CD47 mAb is Fc and Ca21 independent. Monocytes (106/ml) were stimulated with SAC and IFN-g and
titrated concentrations of F(ab9)2 anti-CD47 mAb (A) or 20 mg/ml of Fab anti-CD47, EDTA, and EGTA (5 mM) (B). IL-12p70 and TNF-a release were
measured after 20 h. Results in A represent mean values of one out of three separate experiments using three different donors. Results in B are expressed as
means 6 SD of percent inhibition of control response (SAC- and IFN-g–treated monocytes) of four separate experiments using four different donors.1179 Armant et al.
suppressed IL-12 regardless of the presence of divalent cat-
ion chelating agents.
CD47 antigen, also named integrin-associated protein
(IAP), regulates the function and the binding of Vn to avb3,
its associated integrin (13). However, Vn does not bind
CD47, and the natural ligand of CD47 is reported to be
TSP (16). TSP interacts with CD47 through its CBD, but
binds other surface receptors such as CD36 or avb3 via
distinct domains (17, 24).
Since TSP reportedly activates latent TGF-b in vitro and
in vivo (25) and ligation of CD36 by CD36 mAb down-
regulates IL-12 and TNF-a production and increases IL-10
(26), we used 4N1K peptide encoding the CBD of TSP to
demonstrate that TSP-mediated inhibition of IL-12 re-
sulted from its direct effect on CD47 antigen. In addition,
CD47 ligation did not decrease TNF-a nor increase IL-10
production. Note that TSP uses its properdin-like domain
to activate TGF-b (17) and that TGF-b production was
not upregulated after CD47 signaling (Fig. 1 C).
IL-12 downmodulation, in the absence of TNF-a inhi-
bition, was also observed in IFN regulatory factor (IRF-1
[27]) and IFN consensus sequence binding protein (ICSBP)-
deficient mice (28). These two transcription factors belong
to the IRF family and bind IL-12p40 promoter as well as
other IFN-stimulated genes. As a direct consequence of the
primary defect in IL-12 production, the deficient mice dis-
played an impaired Th1 response and IFN-g–dependent
host resistance to intracellular pathogens. Similarly, our un-
published observations indicate that CD47 signaling strongly
impaired IL-12–induced proliferative and IFN-g responses
of activated T cells. The role of CD47 antigen, which is
expressed by all leukocytes, has been demonstrated in the
transendothelial migration of neutrophils, lymphocytes, and
more recently, monocytes (15). Our present findings reveal
that CD47 ligation by TSP modulates the function of mono-
cytes. Therefore, we propose that engagement of CD47 is a
novel and unexplored pathway to selectively downregulate
IL-12 production. Inhibition of the IL-12 response is cru-
cial for the treatment of organ-specific autoimmune diseases
(1). For instance, administration of anti–IL-12 mAb com-
pletely abrogated established colitis of trinitrobenzene sul-
fonic acid (TNBS)-treated mice. IL-12 neutralization was also
revealed to be an effective treatment of autoimmune en-
cephalitis and insulin-dependent diabetes.
Finally, in addition to its ability to downregulate IL-12
response through its CBD, TSP is known to display several
important antiinflammatory activities via distinct domains.
TSP facilitates elimination of apoptotic cells (29), activates
TGF-b in vivo and in vitro (25), potently inhibits angio-
genesis (17), and suppresses HIV infectivity through its
binding to HIVg120 (24). Moreover, absence of TSP
causes pneumonia (30). Therefore, since TSP is transiently
expressed at high concentration in damaged and inflamed
tissue, its selective suppression of the IL-12 response
through interaction with the CD47 molecule may be rele-
vant in limiting the duration and the intensity of the inflam-
matory response. The importance of such a process awaits
confirmation in CD47- and TSP-deficient mice.
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Figure 4. PI 3-K inhibitors restore IL-12 production. Monocytes (106/ml) were stimulated with SAC and IFN-g in the absence or presence of CD47
mAb (10 mg/ml) and titrated concentrations of wortmannin or Ly294002. IL-12p70 release was measured after 20 h. Results represent mean values from
one of three independent experiments using three different donors.1180 CD47 Regulation of IL-12 Production
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